Writing the Worldwide Marketing Authorisation Status Section in a PBRER

Introduction

The Worldwide Marketing Authorisation Status section provides regulators with an overview of the current global regulatory status of the medicinal product. Although this section is primarily descriptive, it establishes important context for the scientific discussions that follow. Regulatory approvals, withdrawals, suspensions and restrictions may all influence interpretation of subsequent safety information and provide insight into the evolving benefit-risk profile of the product.

New authors sometimes regard this section as an administrative exercise that merely documents where a medicinal product is marketed. In reality, changes to worldwide marketing status frequently reflect important regulatory decisions arising from safety, efficacy or quality considerations. Understanding these changes assists regulatory assessors in interpreting subsequent discussions within the PBRER.

The objective is therefore not simply to present a list of countries but to provide sufficient regulatory context to support the cumulative benefit-risk assessment.

Regulatory Basis

The Worldwide Marketing Authorisation Status section is described within ICH E2C(R2) and incorporated into the European Union PBRER/PSUR framework through GVP Module VII.

The guidance expects Marketing Authorisation Holders to summarise the worldwide regulatory status of the medicinal product and identify important changes occurring during the reporting interval. The emphasis should remain on information relevant to interpretation of the product's benefit-risk profile rather than comprehensive administrative listings.

Regulatory Basis

• ICH E2C(R2): Worldwide Marketing Authorisation Status.

• EMA Good Pharmacovigilance Practices (GVP) Module VII.

Purpose of this Section

This section establishes the global regulatory context in which the benefit-risk assessment should be interpreted.

Marketing authorisation status may influence exposure, prescribing practices, regulatory expectations and post-authorisation safety activities. Significant changes to authorisation status may also indicate that important regulatory concerns have arisen during the reporting interval.

Examples include:

• Initial marketing authorisations.
• New country approvals.
• Withdrawals from specific markets.
• Suspension or revocation of marketing authorisations.
• Restrictions to approved indications.
• Changes affecting availability of the product.

Not every regulatory change requires detailed discussion. The emphasis should remain on developments that contribute to understanding of the medicinal product's evolving regulatory history or benefit-risk profile.

Complex Global Marketing Authorisation Models

For many medicinal products, preparation of the Worldwide Marketing Authorisation Status section is straightforward because a single Marketing Authorisation Holder owns all worldwide licences. In practice, however, many products are commercialised through considerably more complex licensing arrangements involving affiliates, distributors, licensing partners, co-marketing agreements or regional commercial partners.

These arrangements can make preparation of this section significantly more challenging. The objective of the PBRER is not to describe every contractual relationship but to provide regulators with an accurate understanding of the worldwide regulatory status of the medicinal product and any important changes that may influence interpretation of the benefit-risk assessment.

The author should therefore understand the commercial and regulatory ownership model before preparing this section.

Global Marketing Authorisation Holder and Local Marketing Authorisation Holders

Many multinational pharmaceutical companies operate using a global development model combined with regional or local Marketing Authorisation Holders.

For example, the medicinal product may be developed centrally by one company while individual marketing authorisations are held by affiliated legal entities in different countries. Although the legal Marketing Authorisation Holder differs between jurisdictions, pharmacovigilance activities may be coordinated through a single global safety organisation.

In these situations, the Worldwide Marketing Authorisation Status section should focus on the regulatory status of the medicinal product rather than differences in corporate legal structure. Individual local Marketing Authorisation Holders generally do not require detailed discussion unless their regulatory status differs in a manner that materially affects the benefit-risk assessment or regulatory history of the product.

Licensing, Co-Marketing and Commercial Partners

Commercial partnerships introduce additional complexity.

A medicinal product may be:

• licensed into particular countries,
• licensed out to regional partners,
• co-promoted by multiple companies,
• marketed under different trade names,
• commercialised by distributors,
• supplied under public-sector procurement agreements.

The purpose of this section is not to document every commercial agreement. Instead, authors should determine whether the arrangement affects interpretation of worldwide regulatory status or pharmacovigilance activities.

For example, if a regional licensing partner receives a new marketing authorisation or voluntarily withdraws the product because of commercial reasons unrelated to safety, this may require only brief description. Conversely, suspension of a licence because of an important safety concern would usually warrant clear discussion because it contributes directly to understanding of the medicinal product's benefit-risk profile.

Different Trade Names and Product Presentations

Some medicinal products are marketed internationally under different proprietary names, with different presentations, strengths or authorised indications.

These differences should be considered carefully during preparation of the Worldwide Marketing Authorisation Status section.

The objective is not to catalogue every national variation but to ensure that important regulatory differences relevant to interpretation of the PBRER are communicated clearly.

Where substantial regional differences exist, authors should explain how these differences influence interpretation of worldwide marketing status and subsequent benefit-risk evaluation.

Commercial Versus Safety-Related Regulatory Changes

One of the most important judgements required in this section is distinguishing commercial decisions from regulatory actions driven by benefit-risk considerations.

Products are frequently withdrawn from individual markets because of commercial strategy, manufacturing changes, portfolio rationalisation or low sales. Such withdrawals generally have limited relevance to scientific assessment of the medicinal product unless they influence worldwide exposure or pharmacovigilance activities.

By contrast, withdrawals, suspensions or restrictions resulting from safety, efficacy or quality concerns are scientifically important and should be described clearly because they provide essential context for subsequent discussions within the PBRER.

The report should therefore distinguish clearly between commercial market changes and regulatory decisions reflecting changes in the benefit-risk assessment.

Medical Review Consideration

Whenever a marketing authorisation has been withdrawn, suspended or significantly restricted during the reporting interval, the reviewing physician should confirm whether the underlying reason was commercial, regulatory, quality-related or safety-related. This distinction frequently influences both the level of discussion required in this section and the interpretation of later sections of the PBRER.

Special Situations

Most PBRERs prepared for established medicinal products involve more complex commercial and regulatory arrangements than a single Marketing Authorisation Holder marketing a product globally. The objective of this section is not to describe every commercial arrangement but to understand how different regulatory models influence the information that should be presented within the PBRER.

A useful approach is to consider three questions before drafting this section.

• Who holds the marketing authorisation?
• Who owns or generates the relevant regulatory and pharmacovigilance information?
• Does the arrangement change the interpretation of the worldwide marketing authorisation status?

The answers determine the level of discussion required.

Marketing Authorisation Ownership Models

Some products have a single global Marketing Authorisation Holder, whereas others are authorised through multiple affiliated legal entities (affiliate MAHs), regional Marketing Authorisation Holders or following transfers of marketing authorisations during the product lifecycle.

The important consideration is the regulatory ownership of the marketing authorisation rather than the corporate structure of the organisation. Where multiple affiliated MAHs exist within the same corporate group, the aggregate report is frequently prepared centrally and submitted by the appropriate legal entities according to regional requirements. In such situations, the article should describe the worldwide regulatory status of the product rather than explaining the internal corporate organisation.

Where a marketing authorisation has been transferred during the reporting interval, the author should consider whether the transfer affects interpretation of the regulatory history, product availability or pharmacovigilance responsibilities. Routine administrative transfers generally require only brief explanation unless they influence the scientific assessment or the scope of the report.

Medical Review Consideration

Confirm that all marketing authorisations within the scope of the PBRER have been considered and that any transfers of ownership during the reporting interval are reflected consistently throughout the report where relevant.

Licensing and Development Partnerships

Many medicinal products are commercialised through licensing arrangements (in-licensing, out-licensing, regional licensing), co-development agreements or strategic partnerships.

These arrangements may influence responsibility for preparing the PBRER, exchanging pharmacovigilance data, maintaining the Company Core Data Sheet, preparing regional submissions or implementing regulatory commitments. However, the Worldwide Marketing Authorisation Status section should focus only on aspects that influence the worldwide regulatory status of the medicinal product.

Commercial agreements themselves rarely require detailed discussion unless they result in changes to marketing authorisations, regulatory responsibilities or the geographical availability of the product.

Authors should avoid describing contractual relationships that do not contribute to understanding of the regulatory status of the medicinal product.

Distributors and Commercial Partners

Commercial distributors, wholesalers, local agents and marketing partners are commonly involved in the supply of medicinal products in many countries. These organisations should not automatically be considered equivalent to Marketing Authorisation Holders.

Where a distributor markets a product on behalf of the Marketing Authorisation Holder, the distributor does not normally assume responsibility for preparation of the PBRER. Nevertheless, distributors may provide information that supports aggregate reporting, including sales data used for exposure estimation or safety information exchanged under Safety Data Exchange Agreements.

The existence of distributors or commercial partners therefore does not usually alter the Worldwide Marketing Authorisation Status section unless the commercial arrangement affects the regulatory status of the product or explains important differences in product availability between countries.

Writing Tip

Distinguish clearly between commercial distribution arrangements and regulatory ownership of the marketing authorisation. These are frequently confused but have different implications for aggregate reporting.

Regional Regulatory Differences

The same medicinal product may have different authorised indications, strengths, pharmaceutical formulations, dosage forms, proprietary names, prescribing information or risk minimisation measures in different regions.

These differences should not be described routinely. Instead, the author should evaluate whether they materially influence interpretation of the worldwide regulatory status or the benefit-risk assessment presented elsewhere within the PBRER.

For example, a difference in trade name is rarely scientifically important. Conversely, approval of a new indication in a major region, introduction of additional contraindications or implementation of significant risk minimisation measures may provide important regulatory context and should therefore be discussed appropriately.

The emphasis should remain on differences that influence regulatory assessment rather than cataloguing national variations.

Regulatory Actions and Market Changes

Changes to worldwide marketing status may occur for many reasons and should not automatically be interpreted as changes in the benefit-risk balance.

Administrative changes include transfers of marketing authorisations, company mergers, portfolio rationalisation, commercial withdrawals, manufacturing discontinuations and strategic decisions to cease marketing in particular countries.

Regulatory actions may include suspension of marketing authorisations, revocation, restriction of indications, introduction of new contraindications or other actions arising from evaluation of safety, efficacy or quality data.

These situations should be distinguished clearly because they have different scientific implications. Commercial decisions generally provide limited information regarding the benefit-risk profile of the medicinal product, whereas regulatory actions arising from scientific review frequently require corresponding discussion within later sections of the PBRER, including the integrated benefit-risk evaluation where appropriate.

Inspection Insight

Where marketing authorisations have been withdrawn or suspended, regulators frequently expect the underlying reasons to be presented accurately and consistently throughout the report. A commercially driven withdrawal should not be presented in a manner that implies deterioration of the benefit-risk balance, while safety-driven regulatory actions should be reflected consistently in all relevant sections of the PBRER.